Physician profile
Mark Allen Hooker
NPI 1467558015
$15,660.77
in general payments reported to CMS, 2019-2025
62 companies · $1,975 in 2025
The $1,975 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,147 · 2020: $2,314 · 2021: $2,874 · 2022: $2,043 · 2023: $2,284 · 2024: $2,024 · 2025: $1,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,282.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,257.16 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amarin Pharma, INC. | $1,916.39 | 2019-2023 | |
| Abbvie INC. | $1,443.71 | 2019-2025 | |
| Lilly USA, LLC | $1,056.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $907.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $604.52 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $573.92 | 2021-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $422.69 | 2023-2025 | Veozah |
| Pfizer INC. | $422.20 | 2020-2025 | |
| Gilead Sciences, INC. | $365.08 | 2019-2025 | |
| Amgen INC. | $363.19 | 2019-2025 | Repatha, Repatha, Otezla |
| Esperion Therapeutics, INC. | $360.99 | 2020-2025 | Nexletol |
| Antares Pharma, INC. | $356.10 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Glaxosmithkline, LLC. | $327.20 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $322.34 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hooker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.